A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine

Trial Profile

A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs O-desmethyltramadol (Primary) ; Tramadol
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Syntrix Biosystems
  • Most Recent Events

    • 26 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2017 Planned End Date changed from 31 Jan 2018 to 22 Dec 2017.
    • 14 Dec 2017 Planned primary completion date changed from 28 Jan 2018 to 15 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top